Elan Scraps Tysabri Portion of J&J Deal

September 2009
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p3
The article reports on the decision of Elan Corp. PLC to remove some part of its Johnson & Johnson deal in the U.S. It states that Elan has decided to discontinue its pending negotiations after the federal court determined that the scheme will breach its long-standing Tysabri drug collaboration with Biogen Idec Inc. It adds that Elan has already eliminated its collaboration and financing agreement with Tysabri.


Related Articles

  • Elan Scraps Tysabri Funding Portion of J&J Venture Deal. Hollingsworth, Catherine // BioWorld Today;9/16/2009, Vol. 20 Issue 178, p1 

    The article reports on the removal of Tysabri's financing option in the venture deal of Elan Corp. with Johnson & Johnson (J&J) in 2009. A U.S. federal court argues that without the removal of the option, Elan will be in breach of its Tysabri's drug partnership agreement with Biogen Idec Inc. An...

  • Corrections & Clarifications.  // BioWorld Today;10/22/2010, Vol. 21 Issue 205, p2 

    A correction to the article on Biogen Idec Inc. and Elan Corp. PLC JC virus assay in the October 19, 2010 issue is presented.

  • Would-be Biogen Buyer's Path Clear, Elan in Tysabri Trouble. Hollingsworth, Catherine // BioWorld Today;9/8/2009, Vol. 20 Issue 172, p3 

    The article reports that Elan Corp. has 23 days to develop a plan to retain ownership of its rights to multiple sclerosis drug Tysabri, as ordered by a federal court ruling. The court found that Elan breached a contract with Biogen Idec Inc. after it entered into a new venture with Johnson &...

  • Court rules for Biogen in dispute with Elan, J&J.  // Dow Theory Forecasts;9/14/2009, Vol. 65 Issue 37, p1 

    The article reports on the ruling of a federal judge regarding the violation of Elan Pharmaceuticals Inc. on a partnership agreement with Biogen Idec Inc. relative to the 1.5 billion dollar deal of Elan with Johnson & Johnson (J&J) in the U.S. It notes that the deal offers 50% stake in Tysabri,...

  • Elan Struggling with Tysabri Legal Trouble.  // Bioworld Week;9/14/2009, Vol. 17 Issue 37, p3 

    The article reports on the legal trouble faced by Dublin, Ireland-based Elan Corp. PLC concerning the agreement on the multiple sclerosis drug Tysabri. It notes that a federal court ruled that the company breached the Tysabri agreement with partner Biogen Idec Inc. by entering a new venture...

  • Biogen Acquires Full Tysabri Rights.  // Contract Pharma;Mar2013, Vol. 15 Issue 2, p36 

    The article reports on acquisition of Tysabri drug from biotechnology manufacturing company Elan Corp. PLC by Biogen Idec Inc.

  • Applications to update labelling for Tysabri submitted.  // Reactions Weekly;1/15/2011, Issue 1334, p2 

    The article on the applications submitted by Biogen and Elan to update the labelling for their multiple sclerosis drug Tysabir or natalizumab in order to help stratify the risk of progressive multifocal leukoencephalopathy (PML) associated with the drug.

  • Biogen Idec/Elan: patient pressure may help Tysabri's return.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p22 

    The article focuses on the appeal of Food and Drug Administration towards multiple sclerosis patients regarding their opinion about the Biogen Idec Inc. and Elan Corp. PLC 's drug Tysabri. The agency has agreed to consider the recommendations from independent advisors and testimonies from...

  • Tysabri makers mulling risks, benefits. McGuire, Stephen // Medical Marketing & Media;May2005, Vol. 40 Issue 5, p10 

    Reports that Biogen Idec Inc. and Elan Corp. PLC do not expect to issue a decision on the fate of their jointly marketed multiple sclerosis drug, Tysabri, until the second half of 2005. Results of clinical trials; Biogen and Elan's reasons for voluntarily withdrawing Tysabri from the market in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics